Developing Senolytic Pro-Drugs for Age Related Diseases
Rubedo Life Sciences is developing senolytic therapies for age related diseases. Underpinned by a bioinformatics and computational platform, the company identifies metabolic changes between senescent (stressed and damaged cells that accumulate with age) and healthy cells to design pro-drug strategies to reduce off target side effects.
Mark Gallop, PhD
Marco Quarta, PhD
Genetics & Platform Technologies